Jounce Therapeutics is a clinical-stage immunotherapy company focused on developing cancer treatments. Its lead product, vopratelimab, is a monoclonal antibody in Phase II clinical trials that activates a protein found on T cells in solid tumors. The company is also developing other antibodies to target different cells and receptors involved in cancer growth. Jounce Therapeutics was founded in 2012 and is based in Cambridge, Massachusetts.